Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer's disease; Part II: open-label extension for participating patients

Next Previous
X
Search
Trial Profile

A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer's disease; Part II: open-label extension for participating patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Marguerite RoAD
  • Sponsors Chugai Pharmaceutical; Roche

    • Most Recent Events

    • 04 Aug 2022 Results comparing ARIA-E severity scales and effects of treatment management thresholds among two phase III clinical studies: SCarlet RoAD and Marguerite RoAD presented at the Alzheimer's Association International Conference 2022
    • 04 Aug 2022 Results investigating the pharmacodynamic effects of gantenerumab on plasma markers for amyloid and tau during NCT01224106 and NCT02051608 (both double-blind and OLE), presented at the Alzheimer's Association International Conference 2022
    • 04 Aug 2022 Results from Marguerite RoAD and other study investigating the association of patient-specific resting state parameters with CSF markers and clinical measures, presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top